glp 1 va coverage GLP-1 for obesity treatment in 13 US states' Medicaid programs Va website says this about
Description
Why do patients stop GLP-1 drugs
Design In the obesity trial, 338 participants (mean age 48 years, 48% women, mean BMI 37.3 kg/m 2 ) were randomised (2:1:1:1:1:2:2) to retatrutide 1 mg, 4 mg (titration), 4 mg (no titration), 8 mg (slow titration), 8 mg (fast titration), 12 mg or placebo over 48 weeks [45]
[Google Scholar] 23.Feldman WB, Tu SS, Alhiary R, Kesselheim AS, Wouters OJ
GLP-1 Drugs and Gastroparesis: What Victims Need to Know Key Takeaways Gastroparesis, or stomach paralysis, has emerged as a significant medical complication linked to GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro
